Background {#s1}
==========

The acromioclavicular (AC) joint can be a frequent but under-diagnosed source of shoulder pain. Zanca, in a case cohort of 1000 patients with 'shoulder pain', described an incidence of AC joint pathology of 12.7%.[@R1] An observational study using MRI demonstrated arthritic changes in up to 48% of the older patient cohort.[@R2]

The AC joint is a diarthrodial joint with a fibrocartilaginous meniscal disc separating the distal clavicle and the acromion. It is stabilised by the capsule, superior and inferior AC ligaments and two coraco-clavicular ligaments (conoid and trapezoid). The AC joint can be prone to injury not only due to its relationship to the shoulder girdle and its position predisposing it to direct trauma, but also due to the biomechanics of the shoulder girdle that require large loads to be transmitted across the small surface area of the joint.

Causes of AC joint pain include primary osteoarthritis (OA), post-traumatic OA and distal clavicular osteolysis (DCO). Primary OA is accepted as a degenerative and progressive age-related condition with changes often presenting by the fourth decade of life.[@R3]Post-traumatic OA is a sequelae of AC joint injury such as AC separation or distal clavicular fractures leading to degenerative changes. DCO was first described in 1936 and can be separated into both traumatic and atraumatic.[@R4]While the pathogenesis of DCO is often debated it has become more commonly accepted as a result of repetitive micro-trauma with resultant underlying subchondral micro-fractures and failed attempts at repair.

The conservative management of AC joint pain involves avoidance of provocative manoeuvres and activities, use of simple analgesics and non-steroidal anti-inflammatories. Taping may be trialled to limit range of motion and reduce compression or traction forces across the joint. Injection of local corticosteroids is considered if the patient fails conservative management though it is accepted the corticosteroids may only provide short-term relief.[@R5] Corticosteroid injections in combination with local anaesthetic are often useful as a diagnostic tool in confirming the source of pain to be the AC joint.

For those patients who fail conservative management and have persistent pain, the accepted surgical approach is to perform a distal clavicular excision. This technique has been shown to reproducibly result in symptomatic relief and return patients to previous levels of activity.[@R7] Both an open or arthroscopic approach may be chosen with both procedures showing comparable long-term outcomes; though arthroscopic resection may have a faster return to previous activities.[@R7]

Complications that have been described following distal clavicular excision include inadequate resection, joint instability and shoulder weakness.[@R8] These complications have been noted using both open and arthroscopic approaches. Instability and resultant weakness are thought to be related to loss of normal AC ligament integrity.[@R9]

The ability of mesenchymal stem cells (MSCs) to differentiate into both osteoblasts and chondrocytes has seen them explored as a cellular therapy for tissue repair and regeneration in OA.[@R12] However, despite their observed multipotency, it is now more commonly accepted that their mechanism of action involves cell to cell and paracrine signalling rather than direct differentiation.[@R15]

There is a growing body of research for the use of biological therapies including MSC therapy in the treatment of symptomatic knee OA. The use of MSC impregnated biological scaffolds and direct intra-articular MSC injections have shown promise in both pre-clinical and clinical studies.[@R16] However, despite this emerging evidence, there is a paucity of literature on the benefits of MSC therapy in small joints or that of the upper limb. The noted potential complications of surgical intervention for symptomatic AC joint pathology suggests that MSC therapy may be a plausible alternative treatment if research indicates reproducible benefit/efficacy.

The aim of this case study was to assess the efficacy of autologous MSC therapy in the treatment of AC joint arthropathy in comparison to previously published results involving large weight bearing joints such as the knee. This case study forms part of a broader ethics approved and registered case series on the effect of MSC therapy in arthritis.

Case presentation {#s2}
=================

A 43-year-old man presented with a painful right shoulder. He had no prior history of injury. The patient was unable to comfortably lift their arm above shoulder height and this significantly impacted on his work and also his recreational sporting pursuits which included swimming and weight lifting. The patient was otherwise well with no relevant medical history.

The patient had previously seen a sports physician and undergone an ultrasound guided corticosteroid injection with complete resolution of pain. Unfortunately, he had recurrence of symptoms shortly after the injection.

MRI of the shoulder showed evidence of advanced AC joint OA. Loss of joint space, capsular thickening, joint inflammation, distal clavicular and acromial subcortical cyst formation and florid clavicular and acromial boney oedema were observed ([figure 1](#F1){ref-type="fig"}).

![Pre-treatment coronal and axial MRI of the shoulder showing evidence of AC joint arthritis with with capsular thickening and joint inflammation (red arrow); florid clavicular and acromial boney oedema (blue arrow); and distal clavicular subcortical cyst formation (black arrow).](bcr-2018-227865f01){#F1}

The patient failed to improve with use of simple analgesia (paracetamol and non-steroidal anti-inflammatories) and activity modification. After careful consideration, and as the patient wished to delay or prevent surgery, the patient commenced autologous adipose-derived MSC (AdMSC) therapy.

The patient received formal written information regarding the use of and relative risks that may be associated with MSC therapy. Prior to commencement of treatment, the patient completed formal written consent.

Investigations {#s3}
==============

MRI of the right shoulder showed evidence of severe AC joint OA with loss of joint space, capsular thickening, joint inflammation/synovitis, distal clavicular and acromial subcortical cyst formation and florid clavicular and acromial boney oedema ([figure 1](#F1){ref-type="fig"}). A repeat MRI was performed at 12 months post-commencement of AdMSC therapy ([figure 2](#F2){ref-type="fig"}).

![Post-treatment coronal and axial MRI showing improvement in features of synovitis with reduced joint effusion (red arrow); reduction in subchondral boney oedema (blue arrow) and significant resolution of subchondral cysts (black arrow).](bcr-2018-227865f02){#F2}

Treatment {#s4}
=========

Autologous adipose-derived stem cell preparation {#s4a}
------------------------------------------------

### Harvest procedure {#s4a1}

Adipose tissue has been shown to be a rich source of autologous MSCs, with AdMSCS having an observed chondrogenic potential.[@R21]

The patient underwent an abdominal lipoharvest procedure which has previously been described in past publications.[@R24] Following the infiltration of 200 mL of tumescent fluid (comprising of 30 mL of 2% lignocaine, 1 mL of 1:1000 epinephrine and 1 mL of 8.4% bicarbonate suspended in normal saline to a total volume of 1000 mL), and using a hand held manual suction technique (a 3 mm lipoaspirate cannula connected to a 20 mL syringe), 40 mL of lipoaspirate was collected. The lipoaspirate was transferred directly from theatre via an air lock to a clean room laboratory on site (Magellan Stem Cells, Melbourne, Australia).

### Isolation and expansion of mesenchymal stem cells {#s4a2}

Isolation and expansion of autologous AdMSCs was performed within a clean room laboratory with equivalent of \>ISO 5 air quality and Class II biological safety cabinets. The process of isolation and expansion has been previously described.[@R24]

At completion of isolation and expansion, the AdMSCs were suspended in a clinical grade MSC cryoprotectant media and cryopreserved using a validated control rate freezing method.[@R24]

### Characterisation and sterility testing {#s4a3}

AdMSCs were characterised as per criteria established by the International Society of Cellular Therapy.[@R29] Flow cytometry fluorescent activated cell sorting (FACS) analysis assessed for the presence of MSC surface markers CD90, CD73 and CD105 and absence of haematopoietic surface markers CD14, CD19, CD34 and CD45 ([table 1](#T1){ref-type="table"}).

###### 

Fluorescent activated cell sorting surface marker analysis showing results consistent with mesenchymal stem cells as per the International Society of Cellular Therapy guidelines

                   Positive markers   Negative markers                                
  ---------------- ------------------ ------------------ ------- ------ ------ ------ ------
  **Percentage**   97.15              98.84              95.16   0.59   0.05   0.69   0.37

At completion of isolation and expansion independent sterility testing for microbial growth/contamination was performed.

AdMSC carrier media preparation {#s4b}
-------------------------------

Autologous conditioned serum was chosen as a carrier media in which to suspend the AdMSCs at time of injection. The combination of MSCs with a blood-derived carrier media has been previously proposed to assist in the expression of collagen Type II and reduce chondrocyte apoptosis.[@R30] Growth factors expressed in ACS including Transforming Growth Factor Beta1 and basic Fibroblast Growth Factor (bFGF) have been shown to assist in migration of stromal cells to the site of injury.[@R30]

A total of 27 mL of whole blood was withdrawn from the patient via venepuncture of an ante-cubital vein and collected in 3 ✕ 9 mL sterile S-Monovette clotting activator tubes (Starstedt, Numbrecht, Germany). The tubes were incubated for 24 hours at 38°C. After the period of incubation, the tubes were then centrifuged at 1000 rpm for 5 min with separation of the plasma and cellular components. The plasma layer was removed and filtered through a 0.2-micron syringe filter (PALL, New York, USA) resulting in a sample of ACS.

Injection method and protocol {#s4c}
-----------------------------

AdMSCs were taken out of cryopreservation and thawed in a sterile water bath with the cyroprotectant media removed using both repeat centrifugation and washing in chilled phosphate buffered saline. The resultant cell pellet was re-suspended in ACS to a total of 1 mL. Cell viability and number was confirmed using a Muse Cell Analyser (Merck, Millipore, USA).

AdMSC therapy was administered at baseline and at 5 months (Week 22).

The patient received a total of 10 million ADMSCs (viability 95.9%) on Day 1 and a total of 8 million AdMSCs (viability 98.3%) at 5 months (Week 22).

Under ultrasound guidance and sterile conditions, a 22 gauge needle was placed into the AC joint using a lateral approach. The AdMSCs were injected with no prior infiltration of local anaesthetic.

Analysis {#s4d}
--------

The following validated outcome questionnaires were completed prior to treatment and prospectively post-treatment:Numeric Pain Rating Scale: The patient rated his shoulder pain over the previous week on a scale of 0--10. The NPRS has been previously validated for using in patients with OA.[@R31]Quick disability of arm, shoulder and hand (QuickDASH): The DASH outcome measure is a validated quality of life measure used to assess disability secondary to upper limb complaints.[@R32] In this case study, the QuickDASH is used which is a two-part assessment consisting of a Disability Score and a Sport Score. The score ranges from 0 (no disability) to 100 (most severe disability). An improvement of 10 points is considered a minimal clinically important difference.[@R33]

Outcome and follow-up {#s5}
=====================

Pain and functional outcome {#s5a}
---------------------------

The patient had consistent improvement in pain throughout follow-up with the NPRS improving from 5 at baseline to 0 at completion of data collection at 18 months ([figure 3](#F3){ref-type="fig"}).

![Numeric Pain Rating Scale showing clinically significant reduction in pain throughout the period of data collection.](bcr-2018-227865f03){#F3}

QuickDASH scores at baseline indicated moderate functional impairment. Both the QuickDASH Disability and Sport scores improved consistently from baseline to final follow-up ([figure 4](#F4){ref-type="fig"}). The DASH sport score achieved a minimal clinically important difference as early as 1 month after commencement of therapy.

![Quick disability of arm, shoulder and hand scores showing improvement in pain and function until completion of follow-up at 18 months.](bcr-2018-227865f04){#F4}

Structural outcome {#s5b}
------------------

Repeat MRI imaging of the shoulder at 12 months showed resolution of synovitis and joint effusion, resolution of subchondral oedema of both the distal clavicle and acromion and improvement in subchondral cyst size ([figure 2](#F2){ref-type="fig"}).

Complications and adverse events {#s5c}
--------------------------------

The patient observed a self-limiting flare up in discomfort following each AdMSC injection which lasted 1--3 days. This did not require additional analgesic medication and did not affect their daily activities and was considered a mild adverse event.

Discussion {#s6}
==========

This case study indicates the successful management of symptomatic AC joint OA with the novel method of intra-articular AdMSC therapy. The patient had previously failed to improve with conventional conservative therapy including use of simple analgesics and corticosteroid injections.

Current management of symptomatic AC joint arthropathy or DCO which fails to respond to conservative therapy includes surgical distal clavicular excision (open or arthroscopic). While this technique has been shown to result in reproducible improvement in pain and function, it is not without complications which may include joint instability, shoulder weakness and possible anaesthetic complication.

Autologous MSC therapy has been increasingly studied in the treatment of symptomatic knee OA, although there are no studies on the use of MSC in small joints or those of the upper limb.[@R18] Importantly, the observed potential benefit in knee OA may not be a reproducible finding in other joints.

In this single case study, the use of autologous AdMSC therapy in symptomatic AC joint arthropathy resulted in clinically significant pain, function and structural improvements. The procedure was well tolerated with only a mild and brief flare up in discomfort observed following MSC therapy.

Past research has observed the age of the cell donor to influence MSC cell senescence and differentiation capacity indicating that the patient's age may influence outcome of therapy.[@R34] The benefit of autologous MSC therapy in an older population needs to be determined. Further, factors including joint instability and co-existant pathology such as rotator cuff pathology or gleno-humeral joint OA may additionally influence outcome.

The results presented in this case study suggest that AdMSCS may prove to be a suitable treatment for symptomatic AC joint or other small joint arthropathy which fails traditional conservative management prior to consideration of surgical intervention.

###### Learning points

-   Acromio-clavicular (AC) joint pathology is an under recognised and a frequent cause of shoulder pain.

-   Current conservative management of AC joint arthropathy and distal clavicular osteolysis (DCO) is limited and frequently ineffective.

-   Surgical management of AC joint arthropathy or DCO through distal clavicular excision is reproducible in outcome but can be associated with complications.

-   Autologous adipose-derived MSC therapy may offer a conservative alternative approach to AC joint pain management prior to consideration of surgery.
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